

## Confirmed Speakers

### Plenary Speakers

#### First Time Disclosure

#### The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders (IL09)



Dr Yves P. AUBERSON  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

#### Derivatives of 1,3,5-triazine as a New Trend in the Search for the 5-HT<sub>6</sub> Receptor Ligands with Therapeutic Perspectives (PL01)



Prof. Jadwiga HANDZLIK  
(MEDICAL COLLEGE OF JAGIELLONIAN UNIVERSITY, Krakow, Poland)

#### Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders (PL02)



Prof. Krzysztof PALCZEWSKI  
(CASE WESTERN RESERVE UNIVERSITY, Cleveland, United States)

#### Next Generation Pain Therapeutics for the Opioid Crisis: Design of Bifunctional Nociceptin/Mu Opioid GPCR Ligands as non-Addicting Analgesics (PL03)



Dr Nurulain ZAVERI  
(ASTRAEA THERAPEUTICS, Mountain View, United States)

### Matrix Metallo-Proteinases

#### Libraries of Fluorogenic Substrates with Natural and Unnatural Amino Acids as a Tool in Design of Active and Specific Probes for Investigation of Proteolytic Enzymes (IL01)



Prof. Marcin DRAG  
(WROCLAV UNIVERSITY OF TECHNOLOGY, Wroclaw, Poland)

#### MMP-9 at the Synapse in the Brain and Mind (IL02)



Prof. Leszek KACZMAREK  
(NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, Warsaw, Poland)

#### Metalloproteinase Cleavage Control of Interferon Alpha and Gamma Dampens Inflammation and Anti-Viral Immunity (IL03)



Prof. Christopher OVERALL  
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

### Chemical Biology Tools & Target Engagement Technologies

## Confirmed Speakers

### Protein-Ligand Interactions: How Medicinal Chemistry Contributes to the Understanding of Molecular Recognition (IL17)



Dr Marc NAZARE  
(FMP, Berlin, Germany)

### Adventures in Targeting Protein Lipidation: Breaking Drug Resistance Using Fragment Deconstruction and Chemical Biology (IL18)



Prof. Edward TATE  
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

### Tankyrase Inhibitors : Evidence for Therapeutic Potential in Immuno-Oncology



Dr Luc VAN HIJFTE  
(MERCACHEMSYNCOM, Nijmegen, The Netherlands)

### GPCRs: a Discovery Powerhouse

#### Design of Orexin 1 Receptor Selective Antagonists (IL11)



Dr Uta LESSEL  
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

#### Next Generation GPR119 Agonists as Potential Treatment for Cardiometabolic Diseases (IL12)



Dr Lothar SCHWINK  
(SANOFI, Frankfurt Am Main, Germany)

#### G Protein-Coupled Receptors: the Structural Basis for their Pharmacology (IL10)



Dr Chris TATE  
(MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom)

### Genomics in Drug Discovery : Roles for Chemistry

#### Designing Synthetic Gene Regulators (SynGR) (IL04)



Prof. Aseem ANSARI  
(UNIVERSITY OF WISCONSIN-MADISON, Madison, United States)

#### Exploring Bacterial Genomes for Natural Product Discovery and Development (IL05)



Prof. Alessandra S. EUSTAQUIO  
(UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, United States)

## Confirmed Speakers

### Integrative Screening Identifies a Novel Node in the Oncogenic YAP/HIPPO Pathway (IL06)



Dr Mathias FREDERIKSEN  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR), Basel, Switzerland)

### Specific and Multi-Targeted Drugs

#### Charting New Paths in Multi-Target Drug Discovery for Alzheimer's Disease (IL13)



Prof. Maria Laura BOLOGNESI  
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

#### Chemical Biology for Drug Discovery: A Click and Play Approach Exemplified by ERK1/2 Probes (OC03)



Dr Charlotte GRIFFITHS-JONES  
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

#### Identification and in-vivo Efficacy Studies of a Nicotinamide Derivative as Novel NNMT Inhibitor (OC04)



Dr Sven RUF  
(SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany)

#### Multiple Targeting - The Histamine H3 Receptor Pharmacophore as Central Element (IL14)



Prof. Holger STARK  
(HEINRICH HEINE UNIVERSITY DÜSSELDORF, Duesseldorf, Germany)

### Targeted Covalent Inhibitors

#### Mining the Protein Kinase Cysteinome (IL22)



Dr Tjeerd BARF  
(ACERTA PHARMA BV, Oss, The Netherlands)

#### Safety First: Covalent Inhibitors from a Safety Perspective (IL20)



Dr Mickael MOGEMARK  
(ASTRAZENECA, Mölndal, Sweden)

#### Adventures in Functional Assignment and Inhibition of Metallo-Enzymes (IL21)



Prof. Christopher J. SCHOFIELD  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

### Adding AI to the Drug Discovery Tool Box

## Confirmed Speakers

### Capturing and Applying Knowledge to Guide Compound Optimisation (OC10)



Mr Nick FOSTER  
(OPTIBRIUM, United Kingdom)

### Learning the Art of Chemical Synthesis with Deep Neural Networks and Discipline Scale Data (IL23)



Prof. Mark WALLER  
(UNIVERSITY OF WOLLONGONG, Wollongong, Australia)

### Applications of Artificial Intelligence in Drug Discovery – Separating Hype From Utility (IL24)



Dr Pat WALTERS  
(RELAY THERAPEUTICS, Cambridge, United States)

### Augmented Intelligence for Compound Design (OC09)



Dr Michal WARCHOL  
(ARDIGEN, Krakow, Poland)

## Advances in Protein Degradation Technologies

### Targeted Protein Degradation with Small Molecules: how PROTACs Work (IL07)



Prof. Alessio CIULLI  
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

### Drugging Challenging E3 Ligases: A Novel Multidisciplinary Approach to Identify Small-Molecules that Bind FBW7 (OC02)



Ms Miriam MARTINEZ CARTRO  
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

### The Ubiquitin System (IL08)



Prof. Huib OVAA  
(LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands)

### Small-Molecule Modulation of Cereblon Protein Level (OC01)



Mr Christian STEINEBACH  
(UNIVERSITY OF BONN, Bonn, Germany)

## Opioid, Pain, Endo-Cannabinoid

### The Discovery and Development of the Clinical FAAH Inhibitor JNJ-42165279 (OC06)

## Confirmed Speakers



Prof. James BREITENBUCHER  
(UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States)

### Potential of Natural Cannabinoids and Synthetic Cannabinoids in Neuroprotection (IL16)



Prof. Rafael FRANCO  
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

### Cannabinoid Receptor Type 2 Modulation to Improve Outcomes for Cartilage Repair in the Osteoarthritic Joint (IL15)



Prof. Katarzyna STAROWICZ-BUBAK  
(INSTITUTE OF PHARMACOLOGY, POLISH ACADEMY OF SCIENCES, Krakow, Poland)

### Discovery of Best in-class, Novel, Selective, Potent and Peripheral FLT3 Inhibitors, a New Way to Treat Neuropathic Pain (OC05)



Dr Dominique SURLERAUX  
(BCI PHARMA, Liège, Belgium)

## Pharma Research Highlights in Poland

### Discovery of OAT-2068 - A Potent, Selective, Orally Bioavailable Inhibitor of Mouse Chitotriosidase and its In Vivo Activity in the Bleomycin-Induced Pulmonary Fibrosis Model in Mice (OC07)



Dr Agnieszka BARTOSZEWICZ  
(ONCOARENDI THERAPEUTICS SA, Warszawa, Poland)

### DPD-inspired Small Heterocyclic Libraries Characterized as Novel LsrK Kinase Inhibitors: an Opportunity to Fight Antimicrobial Resistance (OC08)



Dr Anna KARAWAJCZYK  
(SELVITA, Krakow, Poland)